TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients. - Vicier, Cecile; Sfumato, Patrick; Isambert, Nicolas; Dalenc, Florence; Robert, Marie; Levy, Christelle; Rezai, Keyvan; Provansal, Magali; Adélaïde, José; Garnier, Séverine; Guille, Arnaud; Carbuccia, Nadine; et al. (European Journal of Cancer, 2021)